Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study by Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis by Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan by Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Successful treatment of psoriasis vulgaris with ixekizumab in a patient with concurrent Sjögren's syndrome presenting with dry eye and incomplete SLE by Marina Onda, Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan by Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study by Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis by Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis by Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Connect to this object online.